Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Oxford BioMedica ( (GB:OXB) ) has issued an update.
Oxford Biomedica announced the departure of Robert Ghenchev from its Board of Directors following his exit from Novo Holdings US. This change comes as the company continues to strengthen its position as a leading cell and gene therapy CDMO. Novo Holdings A/S, a major shareholder, retains the right to nominate a new director, subject to board approval, indicating ongoing strategic alignment and potential future developments.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £970.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on GB:OXB Stock
According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.
Oxford BioMedica’s overall score reflects strong earnings call insights and positive corporate events, indicating strategic growth and leadership confidence. However, financial performance challenges and valuation concerns moderate the score.
To see Spark’s full report on GB:OXB stock, click here.
More about Oxford BioMedica
OXB (LSE: OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience, OXB provides viral vector development and manufacturing expertise, collaborating with leading pharmaceutical and biotechnology companies. The company offers a range of technologies for viral vector manufacturing and has facilities in the UK, France, and the US.
YTD Price Performance: 40.0%
Average Trading Volume: 260,365
Technical Sentiment Signal: Buy
Current Market Cap: £706.8M
For an in-depth examination of OXB stock, go to TipRanks’ Overview page.